Technologies

Portfolio Driven by Variety of Technology Platforms

Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.

Captisol®

Summary

Captisol® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Summary

HepDirect™

Summary

HepDirect™ is a prodrug technology that targets the delivery of certain drugs to the liver by using a proprietary chemical modification that renders a drug biologically inactive until cleaved by a liver-specific enzyme.

SUREtechnology Platform™

Summary

The SUREtechnology Platform™, a Selexis, SA technology, is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. Several programs acquired by Ligand are based on this technology.